EMERGING EVIDENCE THAT MAKES A BIG DIFFERENCE

Cost effectiveness

Aspirin as primary
prevention is cost-effective.1

Aspirin use has been shown to save approximately $4.2 million over 5 years.1
In the USA, evidence-based guideline compliant .

The use of aspirin as primary prevention is more cost-effective than no aspirin.2

References

  1. Carlton R, Coppolecchia R, Khalaf-Gillard K, et al. Budget Impact of Appropriate Low-Dose Aspirin Use for Primary and Secondary Cardiovascular Event Prevention in the Managed Care Setting. J Manag Care Spec Pharm. 2018;24(11):1102-1111.
  2. Jiang M, Li P, You JH, et al. Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China. PLoS One. 2019;14(12):e0224580.